- Home
- ONCO vs PRFX Comparison
ONCO vs PRFX Comparison
Compare ONCO & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | PRFX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.7M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONCO | PRFX |
|---|---|---|
| Price | $0.83 | $3.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 480.1K | ★ 1.3M |
| Earning Date | 11-13-2025 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,223,751.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $2.57 |
| 52 Week High | $47.66 | $27.35 |
Technical Indicators
Market Signals| Indicator | ONCO | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 38.02 | 76.82 |
| Support Level | $1.15 | $2.57 |
| Resistance Level | $1.86 | $3.71 |
| Average True Range (ATR) | 0.18 | 0.28 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 2.81 | 72.51 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.